OrthoPediatrics Corp.
16.46-0.45 (-2.66%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · KIDS · USD
Key Stats
Market Cap
412.71MP/E (TTM)
-Basic EPS (TTM)
-1.96Dividend Yield
0%Recent Filings
8-K
8-K
8-K
Q3 revenue up 12%, guidance cut
OrthoPediatrics reported preliminary Q3 2025 net revenue of $61.2 million, up 12% from $54.6 million in Q3 2024, with domestic sales at $48.7 million (14% growth) and international at $12.5 million (6% growth), hampered by delayed 7D capital sales and Latin America orders. The company trimmed its full-year 2025 revenue guidance to $233.5–$234.5 million, down from $237–$242 million, while holding adjusted EBITDA at $15–$17 million and set deployment at $15 million. Revenue timing remains volatile. Yet, core growth persists.
8-K
Board director resigns, new appointment
OrthoPediatrics Corp. accepted Terry Schlotterback's resignation from its Board on August 7, 2025, effective August 8 due to retirement, with no disagreements noted. The Board promptly appointed Kelly Fischer, Senior Vice President and CFO of Cook Medical since 2003, to fill the vacancy through 2026, also joining the Audit and Compensation Committees. Her compensation follows the company's non-employee director policy. Schlotterback's 10,900 unvested shares continue vesting post-retirement.
10-Q
Q2 FY2025 results
OrthoPediatrics posted solid Q2 FY2025 results, with net revenue climbing 16% year-over-year to $61.1M, fueled by 35% growth in scoliosis to $18.5M and 10% in trauma and deformity to $41.7M; gross margin dipped to 72% from 77%, reflecting a higher mix of lower-margin international set sales and 7D units. Operating loss widened to $10.7M from $5.7M, pressured by $3.0M in restructuring charges and rising sales and G&A expenses tied to clinic expansions, while net loss edged up 18% to $7.1M, or $(0.30) per diluted share on 23.5M shares—consistent with reported figures. Cash and short-term investments stood at $70.1M, bolstered by a $25M delayed draw on the Braidwell term loan (now $50M total at SOFR+6.50%, due 2029) alongside a $50M convertible note (4.75%, due 2030); free cash flow not disclosed in the 10-Q. Clinic acquisitions added $314 to goodwill, pushing it to $99.0M. Yet tariffs loom large.
IPO
Employees
Sector
Industry
BSX
Boston Scientific Corporation
100.30-0.67
CNMD
CONMED Corporation
46.71-0.61
DYNT
Dynatronics Corp.
0.05+0.00
ENOV
Enovis Corporation
31.99-0.87
EW
Edwards Lifesciences Corporatio
82.69+0.50
OFIX
Orthofix Medical Inc.
15.32-0.70
SNN
Smith & Nephew SNATS, Inc.
35.78-0.76
SYK
Stryker Corporation
369.59-6.34
TMCI
Treace Medical Concepts, Inc.
6.55-0.29
ZBH
Zimmer Biomet Holdings, Inc.
99.71-1.43